This is a published notice on the Find a Tender service: <u>https://www.find-tender.service.gov.uk/Notice/013177-2025</u>

Award

NP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

F15: Voluntary ex ante transparency notice Notice identifier: 2025/S 000-013177 Procurement identifier (OCID): ocds-h6vhtk-04fd8e Published 4 April 2025, 3:31pm

Section I: Contracting authority/entity

I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

1 South Gyle Crescent

Edinburgh

EH12 9EB

Contact

Cameron Wright

Email

cameron.wright@nhs.scot

Telephone

+44 1312756000

Country

United Kingdom

NUTS code

UKM - Scotland

Internet address(es)

Main address

http://www.nss.nhs.scot/browse/procurement-and-logistics

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA1188 3

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)

II.1.2) Main CPV code

• 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

Supply of Hereditary Angioedema Branded Medicines (Cinryze® and Takhzyro®) to NHS Scotland.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £9,461,558

II.2) Description

II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

The Framework Agreement is for the supply of several hereditary angioedema (HAE) branded medicines to NHS Scotland. The Framework Agreement has been awarded as a single supplier framework agreement to one (1) Framework Participant.

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Negotiated without a prior call for competition

- The works, supplies or services can be provided only by a particular economic operator for the following reason:
 - protection of exclusive rights, including intellectual property rights

Explanation:

Competition for some of the medicines awarded to the Framework Agreement is absent for technical reasons, in accordance with Regulation 33(1)(b)(ii) of the Public Contracts (Scotland) Regulations 2015.

Some of the medicines awarded to the Framework Agreement are protected by exclusive rights, including intellectual property rights, in accordance with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.

IV.1.3) Information about a framework agreement

The procurement involves the establishment of a framework agreement

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract/concession

A contract/lot is awarded: Yes

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract

4 April 2025

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

Takeda UK Limited

1 Kingdom Street

London

W2 6BD

Telephone

+44 770561804

Country

United Kingdom

NUTS code

• UKM - Scotland

The contractor/concessionaire is an SME

No

V.2.4) Information on value of contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: £9,461,556

Section VI. Complementary information

VI.3) Additional information

The estimated value(s) referred to in Section II.1.7 and Section V.2.4 covers the twentyfour (24) month Framework Agreement duration and the twenty-four (24) month extension period of the Framework Agreement. Details of individual lines awarded can be requested from the named person at the head of this notice.

(SC Ref:794852)

VI.4) Procedures for review

VI.4.1) Review body

Sheriff Court House

27 Chambers Street

Edinburgh

EH1 1LB

Email

edinburgh@scotcourts.gov.uk

Telephone

+44 1312252525

Country

United Kingdom

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:

An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or

the Court of Session.

The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.